AstraZeneca plans to increase its investments in Spain. In 2021, the British company invested more than €93 million in Spain, dedicated to innovative projects, and €48 million of that figure were reserved to carry out innovation and development (R&D) projects.
The investment made in 2022 was close to €400 million. Over the past year, the Cambridge-based pharmaceutical company increased its workforce in Spain by 20%, reaching 1,300 employees and planning to hire around a thousand more people in the coming years.
The Government of Spain welcomes the company’s commitment since “it will allow the creation of quality jobs and is in line with the announcements of multimillion-dollar investments from multinationals in all sectors in recent months, and reflects the determined drive that It is being given to the fields of R&D, health, and science with the investments of the Recovery Plan”, the First Vice President of the Government, Nadia Calviño, announced.
If you want to read more about AstraZeneca and the investments the British pharmaceutical company is planning in Spain, download for free our companion app. The Born2Invest mobile app brings you the most important financial news of the day so you can stay informed.
In 2022, AstraZeneca carried out around 300 clinical trials in Spain
The pharmaceutical company conducts clinical trials in different areas, including oncology, cardiovascular diseases, vaccines, and immunotherapy, as well as rare and respiratory diseases. AstraZeneca currently has 179 clinical development programs and of these fifteen are entirely new molecular entities. In the last year, the company carried out, in Spain, nearly 300 clinical trials in which more than 4,500 patients collaborated.
Pascal Soriot, CEO of AstraZeneca has pointed out that “the Spanish R&D ecosystem is first class and we are committed to working with the Spanish Government to unleash the potential of innovative medicines as an engine of long-term economic growth.” He also said that “we will continue to invest and increase our capacities in environments committed to innovation and development.”
The company’s commitment to the Spanish territory can also be seen in the creation of infrastructure since it has allocated a total of €5.5 million for the construction of new offices, as well as the formation of the innovation hub in Madrid.
The company is part of the Partnership for Health System Sustainability and Resilience (Phssr), which has entered into an agreement with the Vall d’Hebron Institute of Oncology (Vhio) to promote preclinical and translational research with other academics, groups, and companies.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [Buffalo Partners]
First, they came for your college campuses. Then they came for your news, your politics, and you entertainment. And now,...
Redeban Boosts its Leadership in Colombia with the Acquisition of SoyYo
The SoyYo brand will be maintained and enters Redeban's portfolio as one of its strategic units. SoyYo is a recognized...
Why the Growth of Real Estate Crowdfunding in Mexico Slows in 2023
An amount that could make real estate crowdfunding more attractive is 500 million pesos or more. Likewise, he added that...
Biomedical Companies in Spain Demand Tax Incentives for R&D Adapted to the Reality of the Sector
There are many companies in the biomedical sector that, being in the investment or expansion phase, have negative or reduced...
Switzerland Will Probably Legalize Cannabis in the Next Four Years
Switzerland has the advantage that it has already introduced legalization tests in various municipalities. Each test can cover up to...
Impact Investing1 week ago
Daze Closes a 15 Million Euro Capital Increase from CDP Venture and EIC-Fund
Mining & Energy2 days ago
Argentina Lithium & Energy Leading the Charge as Demand for Argentine Lithium Grows
Crowdfunding2 weeks ago
Amica’s Crowdfunding to Buy Casa Coll Raised Over 53,000
Crowdfunding1 week ago
How Was 2023 for Seedrs, a UK-Based Crowdfunding Portal